文献速递甲状腺疾病

甲状腺功能减退症与躯体化:E-Mode甲状腺治疗患者自评—一项横断面国际在线患者调查的结果

Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey.
PubMed 文献 · Thyroid · 2023-05-03

该研究为在线多国横断面调查,纳入自报接受治疗的甲状腺功能减退症患者,采用经验证的患者健康问卷-15(PHQ-15)评估躯体化。共收到3915份回复,其中3516份含有效PHQ-15数据,可能躯体症状障碍(pSSD)患病率为58.6%,并与年轻、女性、未工作、家庭收入低于平均水平、单用左甲状腺素(LT4)治疗等因素相关。

要点

  • 甲状腺功能减退症患者中可能躯体症状障碍(pSSD)患病率为58.6%。
  • pSSD与单用左甲状腺素(LT4)治疗、认为药物未良好控制症状相关(p<0.001)。
  • pSSD与对诊疗不满、焦虑及情绪低落/抑郁相关(p<0.001)。

核心结论

  • 本研究表明甲状腺功能减退症患者中可能躯体症状障碍(pSSD)患病率高,且pSSD与不良患者结局相关,包括倾向于将持续症状归因于甲状腺功能减退症或其治疗。
  • 躯体症状障碍(SSD)可能是部分甲状腺功能减退症患者对治疗和护理不满的重要决定因素。

研究设计与样本

  • 在线、多国横断面调查,对象为自报接受治疗的甲状腺功能减退症个体。
  • 调查包含经验证的患者健康问卷-15(PHQ-15)用于评估躯体化;共收到3915份回复,其中3516份含有效PHQ-15数据(89.8%)。
  • 采用带Bonferroni校正的卡方检验比较PHQ-15评分≥10(可能躯体症状障碍[pSSD])与PHQ-15评分<10(无SSD)的受访者结局。

主要发现

  • PHQ-15中位评分为11.3(范围0-30,置信区间10.9-11.3),pSSD患病率为58.6%。
  • pSSD与年轻年龄(p<0.001)、女性(p<0.001)、未工作(p<0.001)、家庭收入低于平均水平(p<0.001)相关。
  • pSSD与接受左甲状腺素(LT4)治疗(而非LT4与左三碘甲状腺原氨酸(LT3)联合、单用LT3或干燥甲状腺提取物治疗)相关(p<0.001)。
  • pSSD与认为所服甲状腺药物未良好控制甲状腺功能减退症症状(p<0.001)及合并症数量(p<0.001)相关。
  • pSSD与受访者将多数PHQ-15症状归因于甲状腺功能减退症或其治疗(p<0.001)、对甲状腺功能减退症的诊疗不满(p<0.001)、甲状腺功能减退症对日常生活的负面影响(p<0.001)以及焦虑和情绪低落/抑郁(p<0.001)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Between 10% and 15% of hypothyroid patients experience persistent symptoms despite achieving biochemical euthyroidism. Unexplained persistent symptoms can be a sign of somatization. This is associated with distress and high health care resource use and can be classified as somatic symptom disorder (SSD). Prevalence rates for SSD differ depending on classification criteria and how they are ascertained, varying between 4% and 25%. As this has not been studied in hypothyroid patients before, the aim of this study was to document somatization in people with hypothyroidism and to explore associations with other patient characteristics and outcomes. Methods: Online, multinational cross-sectional survey of individuals with self-reported, treated hypothyroidism, which included the validated Patient Health Questionnaire-15 (PHQ-15) for assessment of somatization. Chi-squared tests with the Bonferroni correction were used to explore outcomes for respondents with a PHQ-15 score ≥10 (probable somatic symptom disorder [pSSD]) versus a PHQ-15 score <10 (absence of SSD). Results: A total of 3915 responses were received, 3516 of which contained the valid PHQ-15 data (89.8%). The median score was 11.3 (range 0-30 [confidence interval 10.9-11.3]). The prevalence of pSSD was 58.6%. Associations were found between pSSD and young age (p < 0.001), women (p < 0.001), not working (p < 0.001), having below average household income (p < 0.001), being treated with levothyroxine (LT4) (rather than combination of LT4 and L-triiodothyronine [LT3], LT3 alone, or desiccated thyroid extract) (p < 0.001), expression of the view that the thyroid medication taken did not control the symptoms of hypothyroidism well (p < 0.001), and with number of comorbidities (p < 0.001). pSSD was associated with respondent attribution of most PHQ-15 symptoms to the hypothyroidism or its treatment (p < 0.001), dissatisfaction with care and treatment of hypothyroidism (p < 0.001), a negative impact of hypothyroidism on daily living (p < 0.001), and with anxiety and low mood/depression (p < 0.001). Conclusions: This study demonstrates a high prevalence of pSSD among people with hypothyroidism and associations between pSSD and negative patient outcomes, including a tendency to attribute persistent symptoms to hypothyroidism or its treatment. SSD may be an important determinant of dissatisfaction with treatment and care among some hypothyroid patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Perros P, Nagy EV, Papini E, et al. Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey. Thyroid. 2023. PMID: 37134204. doi:10.1089/thy.2022.0641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。